Speedier Drug Approvals Hit Slowdown as FDA Faces Scrutiny

December 7, 2022by Matthew Perrone, Associated Press Health Writer
Speedier Drug Approvals Hit Slowdown as FDA Faces Scrutiny
A sign in front of the Food and Drug Administration building is seen on Dec. 10, 2020, in Silver Spring, Md. (AP Photo/Manuel Balce Ceneta, File)

WASHINGTON (AP) — Expedited drug approvals slowed this year as the Food and Drug Administration’s controversial accelerated pathway came under new scrutiny from Congress, government watchdogs and some of the agency’s own leaders.

With less than a month remaining in the year, the FDA’s drug center has granted 10 accelerated approvals — fewer than the tally in each of the last five years, when use of the program reached all-time highs.

The program allows drugs to launch in the U.S. based on promising early results, before they are proven to benefit patients.

Academics have long complained that the practice has resulted in a glut of expensive, unproven medications, particularly for cancer. But last year’s accelerated approval of a much-debated Alzheimer’s drug touched off a new round of criticism, including investigations of FDA’s decision making by federal inspectors and Congress.

A recent FDA hearing aimed at revoking approval from an unproven preterm birth drug further underscored the program’s shortcomings. FDA has been trying to get the drug, Makena, off the market for more than two years, because a follow-up study showed it didn’t benefit infants or mothers. The manufacturer has refused to cooperate.

Amid the latest controversy, FDA leaders have taken unprecedented steps suggesting a tougher stance on accelerated approval: nudging drugmakers to remove a growing list of unproven uses for drugs and asking Congress for new powers to expedite removals when companies balk.

Dr. Reshma Ramachandran, a Yale University researcher who supports congressional reforms, believes the recent scrutiny of the accelerated approval process “definitely led to them pausing and taking a different path.” Still, Ramachandran and other critics say it’s too early to tell if FDA’s recent actions reflect a longer-term policy shift.

An FDA spokeswoman said the agency’s posture on accelerated approval “has remained consistent and the agency is committed to ensuring the integrity of the program.” She added that FDA is using “every authority at our disposal” to make sure drugmakers quickly conduct confirmatory studies after approval.

Launched in 1992, the accelerated approval program is credited with speeding the availability of early breakthroughs for HIV and cancer. About 300 drug approvals have been made that way, nearly half of them in the last five years.

But researchers and government watchdogs have chronicled problems with FDA’s oversight, including delays in quickly removing drugs with failed or missing confirmatory studies. Federal inspectors recently found that 40% of accelerated approvals had incomplete confirmation studies.

The picture is beginning to change. In less than two years, the FDA has successfully called on drugmakers to remove more than 20 approvals from accelerated drugs — mainly cancer therapies — that failed to show a benefit. That’s more than half the withdrawals in the program’s history.

FDA’s cancer chief, Dr. Rick Pazdur, has referred to this effort of clawing back approvals as his “jihad.”

Several drugmakers recently declined FDA requests to voluntarily pull their drugs. That’s raised the specter of more long, onerous public hearings to force removal, a process Pazdur called “a nightmare.”

The ability to require drugmakers to have their studies underway before approval is one part of legislation that congressional lawmakers hope to attach to a massive, end-of-the-year spending bill. If passed, it would be the biggest overhaul in accelerated approval’s 30-year history.

“We need more teeth in terms of getting the confirmatory trials started before accelerated approval,” FDA Commissioner Robert Califf said at a recent cancer conference. “Once approval occurs it’s very difficult to hold back the marketeers.”

FDA regulators are already testing out the approach. Increasingly, the agency is telling drugmakers they must have their confirmation studies underway before approval.

“We know the FDA has raised the bar for accelerated approval, and so that’s why we’re seeking additional clarity on their position,” Mike Sherman, CEO of startup Chimerix, told investors on a recent call discussing the company’s plans for an upcoming cancer drug.

A higher bar could spell trouble for smaller drugmakers, who often rely on accelerated approval to gain a market foothold before raising additional funds.

To be sure, FDA approval trends are impacted by a variety of forces. The agency’s overall tally of novel drugs is down markedly this year at about 30, compared with 50 last year. And even the recent peak in use of the accelerated pathway — 45 approvals in 2020 — reflected several trends.

Drugmakers have been aggressively pursuing a new class of “immunotherapies” that help the body recognize and attack cancer. The FDA has granted more than 80 uses for those drugs since 2015, pushing up annual accelerated approval tallies.

Additionally, COVID-19 pandemic disruptions forced some drugmakers to cut short their research plans, asking FDA for accelerated approval based on partially completed studies, instead of a full results.

“There was a lot of reinterpretation of the FDA rules to make sure those companies could proceed, otherwise they would have lost billions of dollars,” said Sam Kay, a consultant with Clarivate, which advises pharmaceutical companies.

It’s a reminder of how much flexibility the FDA has.

Many of the reforms pending in Congress “are things the FDA could do now,” notes Ramachandran.

“I think having Congress do it gives them the cover and blessing to carry forward with what they want to do,” she said.

___

Follow Matthew Perrone on Twitter: @AP_FDAwriter

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

A+
a-
  • FDA
  • In The News

    Health

    Voting

    Health

    April 20, 2024
    by Jesse Zucker
    Earth Day Raises Awareness of Environmental Impacts on Health and Wellness

    WASHINGTON — As plants, trees and flowers continue to greet the season, one month into spring marks a worldwide occasion:... Read More

    WASHINGTON — As plants, trees and flowers continue to greet the season, one month into spring marks a worldwide occasion: Earth Day. Earth Day has been observed on April 22 every year since 1970 as a global moment to raise environmental awareness. Let’s look at a... Read More

    EPA Designates Two Forever Chemicals as Hazardous Substances, Eligible for Superfund Cleanup

    WASHINGTON (AP) — The Environmental Protection Agency on Friday designated two forever chemicals that have been used in cookware, carpets and firefighting... Read More

    WASHINGTON (AP) — The Environmental Protection Agency on Friday designated two forever chemicals that have been used in cookware, carpets and firefighting foams as hazardous substances, an action intended to ensure quicker cleanup of the toxic compounds and require industries and others responsible for contamination to pay for... Read More

    April 18, 2024
    by Beth McCue
    Salmonella Outbreak Linked to Fresh Basil 

    ATLANTA — The Centers for Disease Control and Prevention on Thursday issued a food safety alert regarding Infinite Herbs organic... Read More

    ATLANTA — The Centers for Disease Control and Prevention on Thursday issued a food safety alert regarding Infinite Herbs organic basil. As of the alert, 12 Salmonella cases in seven states have been reported. There are no reported deaths. The basil was sold at Trader Joe’s... Read More

    April 17, 2024
    by Dan McCue
    Eli Lilly Obesity Drug Appears to Ease Sleep Apnea Symptoms in Trials

    WASHINGTON — A pair of yearlong clinical trials conducted by the drug maker Eli Lilly appear to show that its... Read More

    WASHINGTON — A pair of yearlong clinical trials conducted by the drug maker Eli Lilly appear to show that its obesity drug, Zepbound, can provide considerable relief to overweight people who have sleep apnea. Though the findings have yet to be published in a peer-reviewed medical... Read More

    Idaho's Ban on Youth Gender-Affirming Care Has Families Desperately Scrambling for Solutions

    Forced to hide her true self, Joe Horras’ transgender daughter struggled with depression and anxiety until three years ago, when... Read More

    Forced to hide her true self, Joe Horras’ transgender daughter struggled with depression and anxiety until three years ago, when she began to take medication to block the onset of puberty. The gender-affirming treatment helped the now-16-year-old find happiness again, her father said. A decision by the... Read More

    Weedkiller Manufacturer Seeks Lawmakers' Help to Squelch Claims It Failed to Warn About Cancer

    DES MOINES, Iowa (AP) — Stung by paying billions of dollars for settlements and trials, chemical giant Bayer has been... Read More

    DES MOINES, Iowa (AP) — Stung by paying billions of dollars for settlements and trials, chemical giant Bayer has been lobbying lawmakers in three states to pass bills providing it a legal shield from lawsuits that claim its popular weedkiller Roundup causes cancer. Nearly identical bills... Read More

    News From The Well
    scroll top